Fig. 4.
NK cells are required in vivo for the anti-tumor response to hu14.18K322A. B6 mice were implanted with 0.5x106 B78D14 tumor cells on day 0, and combination immunotherapy was begun on day 5. Natural killer cells were depleted by injection of αNK1.1 mAb on days −2, 3, and 8 of therapy. a Tumor growth and b survival were monitored over time. * P < 0.05 comparing combination therapy group with all other groups (control, combo + depletion) and was determined by applying a two-way ANOVA. Graphs show groups consisting of 4–6 mice per group and are representative of 2 independent experiments